| Previous close | 2.0000 |
| Open | 2.0200 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 1.00 |
| Expiry date | 2024-09-20 |
| Day's range | 2.0000 - 2.0200 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
ZacksIonis (IONS), Biogen Down on Ending Development of ALS Drug
Ionis (IONS) and Biogen (BIIB) stop developing their experimental ALS drug after a phase I/II study failed to show improvement in patients.
- Zacks
FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing
Per the FDA, the data submitted by Ascendis (ASND) for its hormone replacement therapy constitutes a major amendment to its previously-submitted data. A final decision is expected by Aug 14.
Simply Wall St.Heron Therapeutics, Inc. (NASDAQ:HRTX) Just Released Its First-Quarter Earnings: Here's What Analysts Think
A week ago, Heron Therapeutics, Inc. ( NASDAQ:HRTX ) came out with a strong set of quarterly numbers that could...
© 2024 Yahoo. All rights reserved.